Table 4.
Copper IUD | Ulipristal Acetate | Levonorgestrel | Yuzpe | |||||
---|---|---|---|---|---|---|---|---|
aOR | 95% CI | aOR | 95% CI | aOR | 95% CI | aOR | 95% CI | |
Reproductive Health Specialists | ||||||||
% women of reproductive age in practice | ||||||||
All or most | 3.85* | 1.10–13.52 | 4.38 | 0.56–34.28 | 6.10*** | 2.32–16.06 | 2.30 | 0.79–6.68 |
About half | 2.47 | 0.60–10.24 | 3.14 | 0.33–29.45 | 3.57* | 1.06–11.97 | 0.62 | 0.17–2.28 |
Small proportion | ref | ref | ref | ref | ||||
Provider type | ||||||||
CNM, PA, NP | 0.70 | 0.40–1.23 | 0.70 | 0.33–1.51 | 1.25 | 0.58–2.71 | 0.47** | 0.27–0.83 |
Resident or Fellow | 1.12 | 0.56–2.21 | 0.53 | 0.20–1.39 | 0.34* | 0.15–0.78 | 0.78 | 0.38–1.60 |
Staff Physician | ref | ref | ref | ref | ||||
Non-Reproductive Health Specialists | ||||||||
Specialty | ||||||||
Family Practice | 4.49*** | 2.38–8.48 | 1.44 | 0.64–3.25 | 2.49*** | 1.72–3.62 | 3.25*** | 2.05–5.15 |
Pediatrics/Adolescent | 0.87 | 0.41–1.84 | 1.02 | 0.46–2.26 | 1.71** | 1.23–2.38 | 1.55 | 0.96–2.50 |
Emergency Medicine | 0.23 | 0.05–1.02 | 1.21 | 0.46–3.17 | 4.84*** | 3.17–7.40 | 0.95 | 0.51–1.77 |
Internal Medicine | ref | ref | ref | ref | ||||
% women of reproductive age in practice | ||||||||
All or most | 1.42 | 0.57–3.52 | 5.15*** | 2.29–11.58 | 3.00*** | 1.64–5.50 | 1.76 | 0.93–3.33 |
About half | 1.10 | 0.59–2.04 | 1.05 | 0.50–2.20 | 1.74*** | 1.28–2.35 | 1.37 | 0.91–2.06 |
Small proportion | ref | ref | ref | ref | ||||
Provider type | ||||||||
CNM, PA, NP | 0.29 | 0.09–1.00 | 0.86 | 0.35–2.12 | 0.32*** | 0.22–0.47 | 0.39** | 0.21–0.73 |
Resident or Fellow | 1.08 | 0.46–2.55 | 1.39 | 0.49–3.91 | 1.08 | 0.69–1.71 | 1.44 | 0.76–2.74 |
Staff Physician | ref | ref | ref | ref |
Results shown from multivariate logistic regression; models include the following covariates: years in practice, proportion of practice comprised of by women of reproductive age, practicing in an academic setting, and gender of provider
Significant at p <0.05;
Significant at p <0.01;
Significant at p <0.001